Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic ... 7thSpace Interactive (press release) Exclusion criteria included disease exacerbation within past 30 days; rituximab or cyclophosphamide within 6 months; pregnancy. Vaccine was administered at months 0, 2, and 6. Physical examination, SLEDAI scores and laboratory studies were performed ... |
